Drug Profile
EMZ 702
Alternative Names: EMZ-702; EMZ702 + peginterferon-α + ribavirin; HCV-I.E.T.; HCV-IET; Interferon Enhancing Therapy for hepatitis C - Transition Therapeutics; Pegylated interferon-α + ribavirin + EMZ702Latest Information Update: 08 Aug 2006
Price :
$50
*
At a glance
- Originator Transition Therapeutics
- Class Antivirals; Interferons; Ribonucleosides
- Mechanism of Action Enzyme inhibitors; Immunomodulators; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Aug 2006 Final results from a phase I/II clinical trial in patients with Hepatitis C have been added to the adverse events and Viral Infection therapeutic trials sections
- 28 Apr 2006 Interim results from a phase I/II clinical trial in patients with Hepatitis C have been added to the Viral infections therapeutic trials section
- 29 Jul 2005 Phase-I/II clinical trials in Hepatitis C treatment in Canada (unspecified route)